⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ozone SCHEMBL2338704 | 0.61 | — | — | |
| SCHEMBL1200392 | 0.50 | — | — | |
| SCHEMBL131007 | 0.50 | — | — | |
| SCHEMBL1743328 | 0.50 | — | — | |
| SCHEMBL6312515 | 0.50 | — | — | |
| SCHEMBL45002 | 0.50 | — | — | |
| SCHEMBL29369 | 0.50 | — | — | |
| SCHEMBL434497 | 0.47 | — | — | |
| SCHEMBL36197 | 0.47 | — | — | |
| SCHEMBL2786969 | 0.47 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109498802-B | Compositions and methods for treating carboxyhemoglobinemia | 高等教育联邦系统-匹兹堡大学 | 2021-11-09 | — | — | CN | disclosed |
| CN-109498802-A | For treating the composition and method of carboxyhemoglobinemia | 高等教育联邦系统-匹兹堡大学 | 2019-03-22 | — | — | CN | disclosed |
| CN-105209060-B | Compositions and methods for treating carboxyhemoglobinemia | 高等教育联邦系统-匹兹堡大学 | 2018-12-07 | — | — | CN | disclosed |
| US-9612242-B2 | Combined F2-isoprostane and myleoperoxidase detection, a risk indicator for cardiovascular disease | THE CLEVELAND CLINIC FOUNDATION (US) | 2017-04-04 | — | — | US | disclosed |
| US-9581597-B2 | Myeloperoxidase, a risk indicator for cardiovascular disease | THE CLEVELAND CLINIC FOUNDATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-9575065-B2 | Myeloperoxidase, a risk indicator for cardiovascular disease | THE CLEVELAND CLINIC FOUNDATION (US) | 2017-02-21 | — | — | US | disclosed |
| US-9435808-B2 | Myeloperoxidase, a risk indicator for cardiovascular disease | THE CLEVELAND CLINIC FOUNDATION (US) | 2016-09-06 | — | — | US | disclosed |
| US-20160238605-A1 | MYELOPEROXIDASE, A RISK INDICATOR FOR CARDIOVASCULAR DISEASE | CLEVELAND CLINIC FOUND (US) | 2016-08-18 | — | — | US | disclosed |
| US-20160238604-A1 | MYELOPEROXIDASE, A RISK INDICATOR FOR CARDIOVASCULAR DISEASE | CLEVELAND CLINIC FOUND (US) | 2016-08-18 | — | — | US | disclosed |
| US-20160238603-A1 | MYELOPEROXIDASE, A RISK INDICATOR FOR CARDIOVASCULAR DISEASE | CLEVELAND CLINIC FOUND (US) | 2016-08-18 | — | — | US | disclosed |
| US-20060105408-A1 | determining total protein bound or total free levels or both of one or more myeloperoxidase (MPO)-generated amino acids in a bodily sample of blood, serum, plasma, or urine from the patient | THE CLEVELAND CLINIC FOUNDATION | 2006-05-18 | — | — | US | disclosed |
| US-20050239136-A1 | Risk markers for cardiovacular disease | THE CLEVELAND CLINIC FOUNDATION | 2005-10-27 | — | — | US | disclosed |
| WO-2005055810-A2 | RISK MARKERS FOR CARDIOVASCULAR DISEASE | THE CLEVELAND CLINIC FOUNDATION (US) | 2005-06-23 | — | — | WO | disclosed |
| EP-1495132-A2 | SYSTEMIC MARKER FOR MONITORING ANTI-INFLAMMATORY AND ANTIOXIDANT ACTIONS OF THERAPEUTIC AGENTS | THE CLEVELAND CLINIC FOUNDATION (US) | 2005-01-12 | — | — | EP | disclosed |
| EP-1353666-A4 | MYELOPEROXIDASE, A RISK INDICATOR FOR CARDIOVASCULAR DISEASE | CLEVELAND CLINIC FOUNDATION (US) | 2004-03-31 | — | — | EP | disclosed |
| WO-2003088814-A2 | SYSTEMIC MARKER FOR MONITORING ANTI-INFLAMMATORY AND ANTIOXIDANT ACTIONS OF THERAPEUTIC AGENTS | THE CLEVELAND CLINIC FOUNDATION (US) | 2003-10-30 | — | — | WO | disclosed |
| EP-1353666-A2 | MYELOPEROXIDASE, A RISK INDICATOR FOR CARDIOVASCULAR DISEASE | THE CLEVELAND CLINIC FOUNDATION (US) | 2003-10-22 | — | — | EP | disclosed |
| US-20030180218-A1 | Systemic marker for monitoring anti-inflammatory and antioxidant actions of therapeutic agents | THE CLEVELAND CLINIC FOUNDATION | 2003-09-25 | — | — | US | disclosed |
| US-20020164662-A1 | Myeloperoxidase, a risk indicator for cardiovascular disease | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-11-07 | — | — | US | disclosed |
| WO-2002062207-A2 | MYELOPEROXIDASE, A RISK INDICATOR FOR CARDIOVASCULAR DISEASE | THE CLEVELAND CLINIC FOUNDATION (US) | 2002-08-15 | — | — | WO | disclosed |